(Reuters) - Celgene Corp said a drug being tested to treat a type of arthritis that affects the spine failed to meet the main goal in a late-stage trial, sending the company's shares down 3 percent premarket.




Source: Celgene's spondylitis drug misses main goal in trial


David Cottle

UBB Owner & Administrator